{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:53:05Z","timestamp":1791359585353,"version":"4.3.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with persistent atrial fibrillation (PersAF), initial treatment strategies often involve rate or rhythm control before offering ablation. This study compared two approaches: (1) catheter ablation without prior medication (referred to as direct-to-catheter ablation, DTCA) and (2) catheter ablation after initial rate control with either diltiazem or metoprolol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study included two independentanalyses of patients with persistent atrial fibrillation (PersAF) undergoing catheter ablation. Aimed at evaluating the potential impact of pre-ablation rate control medications including beta blockers and calcium channel blockers on post-ablation outcomes. Comparison 1: DTCA without prior beta-blocker use (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009209) vs. metoprolol use prior to ablation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009260). Comparison 2: DTCA without prior calcium channel blocker use (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009639) vs. diltiazem use prior to ablation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200955).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were followed for 18 months to evaluate primary outcome: recurrence of atrial fibrillation (AF) and secondary outcomes: Pre-ablation and Post-ablation left atrial percent fibrosis as seen on LGE MRI and Quality of life (QoL), measured with the SF-36 questionnaire. The Wilcoxon tests were conducted to compare the QoL and fibrosis among groups. Time to recurrence among the groups post ablation was assessed via Kaplan-Meier curves. Multivariable Cox models were developed to adjust for other confounders of AF recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the beta-blocker analysis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009469), no significant difference in AF recurrence was observed between patients without prior beta-blocker use (DTCA group) and those treated with metoprolol (Kaplan-Meier,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Similarly, in the calcium channel blocker analysis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009694), no difference in recurrence was found between the DTCA group and those with prior diltiazem use (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Multivariable Cox models confirmed that neither metoprolol (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.44) nor diltiazem (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.34) independently predicted AF recurrence. Additionally, no significant differences were found in imaging metrics or QoL between the groups in either comparison (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prior treatment with diltiazem or metoprolol before ablation of PersAF did not show additional benefits in reducing patient outcomes such as AF recurrence, fibrosis, or improving QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-025-02218-1","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T03:18:19Z","timestamp":1767669499000},"page":"1221-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-ablation rate control therapy and direct-to-catheter ablation in patients with persistent atrial fibrillation: A DECAAF II subanalysis"],"prefix":"10.1007","volume":"69","author":[{"given":"Radia","family":"Ksayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Tsakiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella Gonzalez","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Bidaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Massad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh C.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassir F.","family":"Marrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2218_CR1","doi-asserted-by":"publisher","unstructured":"Linz D, Gawalko M, Betz K, et al. Atrial fibrillation: epidemiology, screening and digital health. The Lancet Regional Health \u2013 Europe. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100786.","DOI":"10.1016\/j.lanepe.2023.100786"},{"issue":"1","key":"2218_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1\u2013156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"issue":"5","key":"2218_CR3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s11739-025-04006-1","volume":"20","author":"G Boriani","year":"2025","unstructured":"Boriani G, Mei DA, Vitolo M, Imberti JF. The 2024 ESC guidelines on atrial fibrillation: essential updates for everyday clinical practice. Intern Emerg Med. 2025;20(5):1299\u2013306. https:\/\/doi.org\/10.1007\/s11739-025-04006-1.","journal-title":"Intern Emerg Med"},{"issue":"14","key":"2218_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2019422.","journal-title":"N Engl J Med"},{"key":"2218_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-024-01916-6","author":"H Younes","year":"2024","unstructured":"Younes H, Ademi B, Tsakiris E, et al. Direct-to-catheter ablation versus second line catheter ablation for persistent atrial fibrillation: effect on arrhythmia recurrence, AF burden, early left atrium remodeling and quality of life. J Interv Card Electrophysiol. 2024. https:\/\/doi.org\/10.1007\/s10840-024-01916-6.","journal-title":"J Interv Card Electrophysiol"},{"issue":"4","key":"2218_CR6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/jce.14957","volume":"32","author":"NF Marrouche","year":"2021","unstructured":"Marrouche NF, Greene T, Dean JM, et al. Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: the DECAAF II trial: study design. J Cardiovasc Electrophysiol. 2021;32(4):916\u201324. https:\/\/doi.org\/10.1111\/jce.14957.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"23","key":"2218_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"DG Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825\u201333. https:\/\/doi.org\/10.1056\/NEJMoa021328.","journal-title":"N Engl J Med"},{"key":"2218_CR8","doi-asserted-by":"publisher","unstructured":"Packer DL, Mark DB, Robb RA, et al; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261\u20131274. https:\/\/doi.org\/10.1001\/jama.2019.0693","DOI":"10.1001\/jama.2019.0693"},{"issue":"4","key":"2218_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","volume":"384","author":"OM Wazni","year":"2021","unstructured":"Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2029554.","journal-title":"N Engl J Med."},{"issue":"2","key":"2218_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/europace\/euad010","volume":"25","author":"M Meyer","year":"2023","unstructured":"Meyer M, Lustgarten D. Beta-blockers in atrial fibrillation\u2014trying to make sense of unsettling results. EP Europace. 2023;25(2):260\u20132. https:\/\/doi.org\/10.1093\/europace\/euad010.","journal-title":"EP Europace"},{"issue":"Suppl 5","key":"2218_CR11","first-page":"V16","volume":"22","author":"HN Sabbah","year":"1999","unstructured":"Sabbah HN. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol. 1999;22(Suppl 5):V16-20.","journal-title":"Clin Cardiol."},{"issue":"3","key":"2218_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.15420\/ecr.2019.30.2","volume":"14","author":"I Garvanski","year":"2019","unstructured":"Garvanski I, Simova I, Angelkov L, Matveev M. Predictors of recurrence of AF in patients after radiofrequency ablation. Eur Cardiol. 2019;14(3):165\u20138. https:\/\/doi.org\/10.15420\/ecr.2019.30.2.","journal-title":"Eur Cardiol"},{"issue":"4","key":"2218_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10557-021-07248-1","volume":"37","author":"MH Strauss","year":"2023","unstructured":"Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drugs Ther. 2023;37(4):757\u201370. https:\/\/doi.org\/10.1007\/s10557-021-07248-1.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"2218_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCEP.108.784272","volume":"1","author":"Z Lu","year":"2008","unstructured":"Lu Z, Scherlag BJ, Lin J, et al. Atrial fibrillation begets atrial fibrillation. Circ Arrhythm Electrophysiol. 2008;1(3):184\u201392. https:\/\/doi.org\/10.1161\/CIRCEP.108.784272.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"2218_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/s0008-6363(02)00258-4","volume":"54","author":"M Allessie","year":"2002","unstructured":"Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230\u201346. https:\/\/doi.org\/10.1016\/s0008-6363(02)00258-4.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"2218_CR16","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1161\/01.cir.92.7.1954","volume":"92","author":"MC Wijffels","year":"1995","unstructured":"Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954\u201368. https:\/\/doi.org\/10.1161\/01.cir.92.7.1954.","journal-title":"Circulation"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-02218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-025-02218-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-02218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:30:34Z","timestamp":1791358234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-025-02218-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1007\/s10840-025-02218-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7672338\/v1","asserted-by":"object"}]},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}